BetaGlue is an Italian biotech company developing next-generation nuclear therapies for solid tumors.
Born at the crossroads of biotechnology, radiochemistry, and interventional oncology, BetaGlue was founded with a single purpose: to turn nuclear science into targeted, effective treatments for cancers with limited therapeutic options.
From our headquarters in Italy, we collaborate with clinicians, scientists, and partners across Europe and the U.S. to bring innovative radiotherapeutics closer to patients who need them most.
Targeted nuclear medicine, redefined.
BetaGlue’s platform delivers radiation precisely where it matters most — inside the tumor.
Our lead program, YntraDose, enables interventional oncologists to deposit a therapeutic payload of beta-emitting isotopes directly within the tumor mass. This localized delivery aims to maximize tumor control while minimizing systemic exposure, making it a promising solution for pancreatic cancer and other hard-to-treat solid tumors.
We are opening new frontiers in precision oncology.
Pioneering earlier, effective treatments for any patient in an accessible and impactful way.
Leading with Data and Passion.
Our ethos combines data-driven analysis, determination, and a passion to redefine how solid tumors are treated locally. By embracing these qualities, we ensure our approach is innovative, informed and resilient, making every advancement a step towards excellence.
Ethical Excellence as Our Standard.
Ethics, professionalism, and transparency guide our every step, forming the bedrock of our interactions with each other, our partners, patients and stakeholders. This unwavering commitment to integrity drives us to new frontiers in precision oncology, building trust and dignity in all we do.
Constantly Improving Patient Outcomes.
Our dedication to innovation focuses on improving patient outcomes, making each breakthrough a leap towards more effective and compassionate care. We’re committed to not just advancing the science of durable local tumor control, but ensuring these advancements directly benefit those we serve, with access and availability wherever we can.
Fostering Empathy and Inclusivity.
Our pioneering efforts in precision oncology are fuelled by empathy and the celebration of diversity. By prioritizing understanding and mutual respect, we are creating an environment where innovation is driven by a genuine desire to improve lives.
BetaGlue partners with pharmaceutical companies, interventional radiology networks, and academic hospitals to advance clinical research, co-develop combination therapies, and scale manufacturing capabilities. Together, we aim to build the next generation of targeted radiotherapeutics that integrate seamlessly into modern cancer care.
Our on-going early feasibility study in locally advanced pancreatic cancer is taking place in the following hospitals.
Our ambition is to make durable local tumor control a standard component of future precision oncology — an approach designed to complement next-generation systemic therapy rather than replace it.
